Exicure, Inc. is a biopharmaceutical company focused on developing novel therapeutics based on the technology of therapeutic coding. Its main product platform is based on a technology called Spherical Nucleic Acid (SNA™), which enables the creation of three-dimensional structures of nucleic acids that have the potential to modulate gene expression. Exicure aims to utilize this technology to develop therapeutics for various indications, including oncological diseases, dermatological conditions, and neurological disorders. The company also engages in research and development of therapeutic vaccines based on SNA™ technology. Exicure collaborates with pharmaceutical companies and academic institutions on the development and commercialization of its products. Shares of Exicure, Inc. may be an interesting investment opportunity for investors following the pharmaceutical industry and biopharmaceutical research.
Feed
There are no posts to show right now.
Używamy ciasteczek, aby ulepszyć Twoje doświadczenie na naszej stronie.
